![]() The P/E ratio is the most commonly used of these ratios because it focuses on the Rapt Therapeutics' earnings, one of the primary drivers of an investment's value. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. ![]() This chart shows the closing price for RAPT for. The average price target represents a 71.90 upside from the last price of 35.00. The average price target is 60.17, with a high forecast of 72.00 and a low forecast of 49.00. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. This price target is based on 6 analysts offering 12 month price targets for RAPT Therapeutics in the last 3 months. This model doesn't attempt to find an intrinsic value for Rapt Therapeutics' Stock. Comparative valuation analysis is a catch-all model that can be used if you cannot value Rapt Therapeutics by discounting back its dividends or cash flows. In a nutshell, if Rapt Therapeutics implied volatility is high, the market thinks the stock has potential for high price swings in either direction. However, it does not forecast the overall direction of its price. The ratio of Current Valuation to Current Liabilities for Rapt Therapeutics is about 4,334 . Rapt Therapeutics implied volatility exposes the markets sentiment of Rapt Therapeutics stocks possible movements over time. It is rated below average in current liabilities category among related companies. Rapt Therapeutics is rated below average in current valuation category among related companies. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |